Clinical Trials | November 26, 2025
Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Poviztra is a second brand of Wegovy
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Subscribe To Our Newsletter & Stay Updated
